Jonathan Baza, DO
Family Medicine · Lumberton, NCNPI 1861840803
Payments from drug & device makers
Across 155 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$486
- Pfizer$242
- Amgen$239
- AstraZeneca$163
- Boston Scientific$157
- Novo Nordisk$157
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,754100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $486 |
| Pfizer | 15 | $242 |
| Amgen(2 entities) | 11 | $239 |
| AstraZeneca | 11 | $163 |
| Boston Scientific | 8 | $157 |
| Novo Nordisk | 11 | $157 |
| Boehringer Ingelheim | 8 | $140 |
| Johnson & Johnson | 7 | $131 |
| Merck | 7 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $78 |
| IBSA Pharma Inc. | 4 | $77 |
| Lilly USA, LLC | 5 | $75 |
| Biohaven Pharmaceuticals, Inc. | 4 | $72 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $52 |
| Inspire Medical Systems, Inc. | 2 | $51 |
| Lucid Diagnostics Inc. | 2 | $50 |
| Organon | 3 | $49 |
| Neurocrine Biosciences, Inc. | 2 | $45 |
| Medtronic | 3 | $44 |
| Nevro Corp. | 1 | $42 |
| Strongbridge US Inc. | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $35 |
| Abbott | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Grifols USA, LLC | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Halozyme Inc | 1 | $17 |
| GSK | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Bayer | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $12 |
How this compares
$2,754 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 67 | $91,877 |
| MounjaroTirzepatide | 56 | $72,314 |
| XareltoRivaroxaban | 44 | $59,676 |
| OzempicSemaglutide | 37 | $40,946 |
| JardianceEmpagliflozin | 25 | $27,886 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $23,094 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $20,859 |
| FarxigaDapagliflozin Propanediol | 23 | $19,692 |
| MyrbetriqMirabegron | 14 | $14,985 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $10,454 |
| Potassium Chloride | 116 | $7,804 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $6,273 |
| Levothyroxine Sodium | 534 | $5,933 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $5,831 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $5,511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $242 | $91,87767 claims |
| Lilly USA, LLCMounjaro | $75 | $72,31456 claims |
| Johnson & JohnsonXarelto | $131 | $59,67644 claims |
| Novo NordiskOzempic | $157 | $40,94637 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $17 | $33,54835 claims |
| Boehringer IngelheimJardiance | $140 | $27,88625 claims |
| AstraZenecaFarxiga | $163 | $19,69223 claims |
| AbbVieSynthroid | $486 | $2,40134 claims |
| Sanofi-aventis U.S. LLCLantus | $21 | $1,91911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Lumberton
- Muhammad ZafarLumberton$244K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.